目的:分析不同预后新型冠状病毒肺炎（新冠肺炎）患者的临床和实验室特征，为新冠肺炎的诊治提供一定依据。方法:回顾性分析2020年1月18日至3月10日天门市第一人民医院收治的215例确诊新冠肺炎患者的临床资料，包括血常规、炎症指标〔C-反应蛋白（CRP）、降钙素原（PCT）〕、肝功能、心功能、肾功能、凝血功能、电解质、胸部CT影像学、新型冠状病毒（2019-nCoV）RNA等标志物。分析并比较不同预后两组新冠肺炎患者上述指标的差异。另选取2019年8月1日至11月30日本院收治的其他病毒性肺炎患者55例为对照组。比较新冠肺炎组和对照组实验室检查指标的差异。结果:入组215例患者中存活206例，死亡9例。生存组年龄明显低于死亡组，住院时间较死亡组明显延长。①临床特征方面：死亡组出现呼吸困难、咽痛、寒战、畏寒等症状及高血压、糖尿病、冠心病、肾脏疾病、外科手术史等比例均明显高于生存组。两组其他症状和体征、基础疾病比例比较差异均无统计学意义。②不同预后两组实验室检查指标方面：死亡组白细胞计数〔WBC（×10n 9/L）：10.6（4.0，13.4）比4.9（3.9，6.3）〕、中性粒细胞计数〔NEU（×10n 9/L）：9.7（3.4，12.2）比2.9（2.1，4.2）〕、中性粒细胞与淋巴细胞比值〔NLR：14.66（5.19，18.48）比2.34（1.47，3.34）〕、C-反应蛋白〔CRP（mg/L）：130.21（35.74，210.86）比17.90（3.11，50.23）〕、降钙素原〔PCT（mg/L）：1.46（0.45，13.12）比0.04（0.02，0.07）〕、乳酸脱氢酶〔LDH（μmol·sn -1·Ln -1）：4.80（3.34，7.37）比3.77（2.99，5.12）〕、肌酐〔Cr（μmol/L）：72.9（69.6，627.5）比68.4（55.5，81.9）〕、D-二聚体〔mg/L：0.86（0.56，3.32）比0.39（0.33，0.58）〕和胸部CT磨玻璃不透明影〔77.8%（7/9）比35.0%（72/206）〕、局部斑片状影〔55.6%（5/9）比17.5%（36/206）〕、双侧片状影〔100.0%（9/9）比49.5%（102/206）〕比例均明显高于生存组（均n P<0.01），淋巴细胞计数〔LYM（×10n 9/L）：0.6（0.5，0.8）比1.3（1.0，1.6）〕、Nan + 〔mmol/L：136.1（131.0，136.8）比138.8（136.5，140.4）〕、Cln - 〔mmol/L：97.7（92.7，100.9）比102.7（100.2，104.3）〕、二氧化碳COn 2 （mmol/L）：23.0（20.6，28.5）比29.2（27.7，30.9）〕水平均明显低于生存组（均n P<0.05）。③新冠肺炎组和对照组实验室检查指标方面：新冠肺炎组WBC、NEU、LYM、血小板计数（PLT）、红细胞分布宽度变异系数（RDW-CV）、红细胞分布宽度标准差（RDW-SD）、Cln -均较对照组明显降低，NLR、CRP、Kn +、COn 2均较对照组明显升高。n 结论:新冠肺炎早期症状以发热、咳嗽、胸闷、乏力为主，高龄和有基础疾病可能是影响新冠肺炎患者预后的危险因素。死亡组和生存组实验室检查指标（WBC、NEU、LYM、CRP、PCT、LDH、Cr）在疾病早期就已经表现出明显异常，对早期预测患者病情有重要意义；同时实验室检查指标（WBC、NEU、LYM、PLT、RDW-CV、RDW-SD、CRP、Cln -、Kn +、COn 2）在新冠患者与其他病毒性肺炎患者的鉴别诊断中也具有重要价值。n “,”Objective:To analyze the clinical and laboratory characteristics of coronavirus disease 2019 (COVID-19) patients with different prognosis, and to provide evidence for the diagnosis and treatment of COVID-19.Methods:The clinical and laboratory characteristics of 215 cases of confirmed COVID-19 patients admitted in the First People's Hospital of Tianmen City from January 18 to March 10, 2020 were retrospectively analyzed, including blood cell indexes, inflammatory indexes [C-reactive protein (CRP) and procalcitonin (PCT)], liver function, cardiac function, renal function, blood coagulation function, electrolyte, chest CT scan, and 2019 novel coronavirus (2019-nCoV) nucleic acid tests. The differences of above indexes in the two groups were compared and analyzed. In addition, 55 patients with other viral pneumonia were selected as the control group who admitted to the hospital from August 1 to November 30, 2019. The changes of laboratory indexes of COVID-19 group and control group were observed.Results:In the 215 patients, 206 patients survived and 9 patients died. The average age of survival group was significantly lower than that in the death group, and the average length of hospital stay was significantly longer than the death group. ① Clinical features: the proportion of underlying diseases in the death group was significantly higher than that in the survival group, such as dyspnea, sore throat, shiver, hypertension, diabetes, coronary heart disease, renal disease, and surgical history. There were no significant differences in other symptoms, signs and underlying diseases between the two group. ② Laboratory test indexes of the two groups: in death group, white blood cell count [WBC (×10n 9/L): 10.6 (4.0, 13.4) vs. 4.90 (3.92, 6.26)], neutrophils count [NEU (×10n 9/L): 9.7 (3.4, 12.2) vs. 2.9 (2.1, 4.2)]; ratio of neutrophils to lymphocytes [NLR: 14.66 (5.19, 18.48) vs. 2.34 (1.47, 3.34)], CRP [mg/L: 130.21 (35.74, 210.86) vs. 17.90 (3.11, 50.23)], PCT [mg/L: 1.46 (0.45, 13.12) vs. 0.04 (0.02, 0.07)], lactate dehydrogenase [LDH (μmol·sn -1·Ln -1): 4.80 (3.34, 7.37) vs. 3.77 (2.99, 5.12)], creatinine [Cr (μmol/L): 72.9 (69.6, 627.5) vs. 68.4 (55.5, 81.9)], D-dimer [mg/L: 0.86 (0.56, 3.32) vs. 0.39 (0.33, 0.58)], the area of ground glass opacity of chest CT scan [77.8% (7/9) vs. 35.0% (72/206)], the area of local patchy shadows [55.6% (5/9) vs. 17.5% (36/206)], the area of bilateral patchy shadows [100.0% (9/9) vs. 49.5% (102/206)] were significantly higher than those in survival group (alln P < 0.01), lymphocyte count [LYM (×10 n 9/L): 0.6 (0.5, 0.8) vs. 1.3 (1.0, 1.6)], Nan + [mmol/L: 136.1 (131.0, 136.8) vs. 138.8 (136.5, 140.4)], Cln - [mmol/L: 97.7 (92.7, 100.9) vs. 102.7 (100.2, 104.3)], and carbon dioxide [COn 2 (mmol/L): 23.0 (20.6, 28.5) vs. 29.2 (27.7, 30.9)] were significantly lower than those in survival group (all n P < 0.05). ③ Laboratory test indicators in COVID-19 and control groups: in COVID-19 group, WBC, NEU, LYM, platelet count (PLT), coefficient of variation of red blood cell distribution width (RDW-CV), standard deviation of red blood cell distribution width (RDW-SD) and Cl n - were significantly lower than those in control group, NLR, CRP, Kn + and COn 2 were significantly higher than those in control group.n Conclusions:The major early symptoms of COVID-19 are fever, cough, chest tightness and fatigue. Age and underlying disease may be the risk factors which affect the prognosis of patients with COVID-19. The laboratory indexes such as WBC, NEU, LYM, CRP, PCT, LDH and Cr between death group and survival group were significantly abnormal in the early stages of COVID-19, which would have important implications for the prognosis of patients with COVID-19. Meanwhile, laboratory test indexes, including WBC, NEU, LYM, PLT, RDW-CV, RDW-SD, CRP, Cln -, Kn + and COn 2, also have important value in the differential diagnosis between COVID-19 and other viral pneumonia.n